Nelistotug clinical trials
Also written GSK6097608.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses nelistotug has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Belrestotug (5) · Remzistotug (2) · Risvutatug rezetecan (1) · Cobolimab (1) · Docetaxel (1) · Feladilimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nelistotug.
- Dec 2026Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsPhase 1 · GlaxoSmithKline
Studies
Open first, then newest update. How each study uses nelistotug has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05565378Written as NelistotugReport a problem
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051Written as NelistotugReport a problem
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingPhase 2GlaxoSmithKlineNCT06062420Written as NelistotugReport a problem
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT04446351Written as GSK6097608Report a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3CompletedPhase 2GlaxoSmithKlineNCT06926673Written as NelistotugReport a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Written as GSK6097608Report a problem
Tested with established drugs · 1 — they are given beside it
Tested in a combination · 5 — another drug in the study is under test too
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05565378Written as NelistotugReport a problem
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051Written as NelistotugReport a problem
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingPhase 2GlaxoSmithKlineNCT06062420Written as NelistotugReport a problem
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT04446351Written as GSK6097608Report a problem
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Written as GSK6097608Report a problem
Codes
What other systems call nelistotug · ClinicalTrials.gg INT015492
- UNII (FDA) 7MCC43O1YBNELISTOTUGOne source FDA
- NCI Thesaurus C176029NelistotugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7MCC43O1YB | NELISTOTUG | One source FDA |
| NCI Thesaurus | C176029 | Nelistotug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.